Technology Insight: identification of biomarkers with tissue microarray technology
- 1 December 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Oncology
- Vol. 1 (2), 104-111
- https://doi.org/10.1038/ncponc0046
Abstract
High-throughput technologies have been developed in the hope of increasing the pace of biomedical research, and accelerating the rate of translation from bench to bedside. Using such technology in target discovery has resulted in the need for systematic validation of the targets in an equally rapid manner. For example, gene expression microarrays have highlighted many potential targets in cancer, and tissue microarrays have emerged as a powerful tool to validate these targets by measuring tumor-specific protein expression and linking it to clinical outcome. Automated quantitative analysis of the tissue microarray 'spots' is beginning to take the technology a step further, removing observer bias, and providing standards for quality control and the potential for high-throughput analysis. The validation required for translation of tissue biomarkers from the research lab to the clinical lab will probably rely heavily on the combination of tissue microarray technology with automated quantitative analysis.Keywords
This publication has 35 references indexed in Scilit:
- ?-Catenin and p53 analyses of a breast carcinoma tissue microarrayCancer, 2004
- Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parametersOncogene, 2004
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarrayBlood, 2004
- The NIH RoadmapScience, 2003
- Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridizationThe Journal of Pathology, 2003
- Cancer Biomarker Validation: Standards and ProcessAnnals of the New York Academy of Sciences, 2003
- Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarraysBlood, 2002
- A Formalin-Fixed, Paraffin-Processed Cell Line Standard for Quality Control of Immunohistochemical Assay of HER-2/neu Expression in Breast CancerAmerican Journal of Clinical Pathology, 2002
- Delineation of prognostic biomarkers in prostate cancerNature, 2001
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998